Beta Drugs Limited (NSE: BETA), ISIN INE351Y01019 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
BETA last traded at ₹2216.30 (-0.76%), with a 52-week range of ₹990.10 to ₹2674.00 (as of 30 Jul 2026).
Shareholding as of Jun 2026: promoters 59.10%, FIIs 1.02%, DIIs 6.23%, mutual funds 0.00%.
EquiSense Score (ECS): 77/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.